Latest & greatest articles for fluoxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluoxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluoxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluoxetine

41. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK

Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK Borghi J, Guest J F Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients in the UK

2000 NHS Economic Evaluation Database.

42. Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France

Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Brown M C, van Loon J M, Guest J F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The new antidepressant drug mirtazapine was compared with fluoxetine. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with moderate (17-Hamilton-Depression, HAM-D, score of 20 to 25) or severe

2000 NHS Economic Evaluation Database.

43. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria

Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria Brown M C J, Nimmerrichter A A, Guest J F Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of mirtazapine, amitriptyline, and fluoxetine in the treatment of moderate and severe depression in Austria. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Austrian people

1999 NHS Economic Evaluation Database.

44. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. Full Text available with Trip Pro

A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. To study the effectiveness of fluoxetine and cognitive-behavioural counselling in depressive illness in postnatal women: to compare fluoxetine and placebo, six sessions and one session of counselling, and combinations of drugs and counselling.Randomised, controlled treatment trial, double blind in relation to drug treatment, with four treatment cells: fluoxetine or placebo plus one (...) in subjects receiving fluoxetine was significantly greater than in those receiving placebo. The improvement after six sessions of counselling was significantly greater than after a single session. Interaction between counselling and fluoxetine was not statistically significant. These differences were evident after one week, and improvement in all groups was complete after four weeks.Both fluoxetine and cognitive-behavioural counselling given as a course of therapy are effective treatments for non

1997 BMJ Controlled trial quality: predicted high

45. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. (Abstract)

Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Major depression affects more than 5% of the population and is a serious health and economic problem. Antidepressants have a slow onset of action and are effective in less than two-thirds of patients. The biochemical effects of selective serotonin reuptake inhibitors may be limited by the negative feedback from serotonin autoreceptors. Pindolol is an antagonist of both (...) serotonin autoreceptors and beta-adrenoceptors. We studied the effect of the addition of pindolol to fluoxetine antidepressant treatment.Of 132 eligible patients with major depression, 111 were randomly assigned to treatment with fluoxetine (20 mg daily) and either placebo or pindolol (7.5 mg daily). Patients were assessed twice a week for the first 3 weeks of active treatment and then once a week until the end of the study (42 days). Hamilton and Montgomery-Asberg depression-rating scales were used

1997 Lancet Controlled trial quality: predicted high

46. Acute medical costs of fluoxetine versus tricyclic antidepressants

Acute medical costs of fluoxetine versus tricyclic antidepressants Acute medical costs of fluoxetine versus tricyclic antidepressants Acute medical costs of fluoxetine versus tricyclic antidepressants Revicki D A, Palmer C S, Phillips S D, Reblando J A, Heiligenstein J H, Brent J, Kulig K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Pharmaceutical: Tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients overdosing on either fluoxetine (SSRI) or tricyclic antidepressants (TCAs). Setting Hospital (emergency departments and intensive care/medical units). The economic study was carried out at 9

1997 NHS Economic Evaluation Database.

47. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. (Abstract)

Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. To compare the clinical, functional, and economic outcomes of initially prescribing fluoxetine with outcomes of initially selecting imipramine or desipramine.Randomized controlled trial.Primary care clinics of a Seattle, Wash, area staff-model health maintenance organization from 1992 through 1994.A total of 536 adults beginning antidepressant treatment for depression.Random (...) assignment of initial antidepressant prescription (desipramine, fluoxetine, or imipramine). Subsequent antidepressant treatment (doses, medication changes or discontinuation, specialty referral) was managed by the primary care physician.Assessments after 1, 3, and 6 months examined clinical outcomes (Hamilton Depression Rating Scale and the depression subscale of the Hopkins Symptom Checklist) and quality-of-life outcomes (Medical Outcomes Study SF-36). Medication use and health care costs were assessed

1996 JAMA Controlled trial quality: uncertain

48. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. (Abstract)

Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. No somatic treatment has been found to be effective for chronic fatigue syndrome (CFS). Antidepressant therapy is commonly used. Fluoxetine is recommended in preference to tricyclic agents because it has fewer sedative and autonomic nervous system effects. However, there have been no randomised, placebo-controlled, double-blind studies showing the effectiveness of antidepressant therapy in CFS. We have (...) carried out such a study to assess the effect of fluoxetine in depressed and non-depressed CFS patients.In this randomised, double-blind study, we recruited 44 patients to the depressed CFS group, and 52 to the non-depressed CFS group. In each group participants were randomly assigned to receive either fluoxetine (20 mg once daily) or placebo for 8 weeks. The effect of fluoxetine was assessed by questionnaires, self-observation lists, standard neuropsychological tests, and a motion-sensing device

1996 Lancet Controlled trial quality: uncertain

49. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. (Abstract)

Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. Premenstrual dysphoria shares certain features with depression and anxiety states, which have been linked to serotonergic dysregulation. We evaluated the efficacy and safety of fluoxetine (which selectively inhibits the reuptake of serotonin) in the treatment of premenstrual dysphoria.The trial consisted of a single-blind, placebo washout period lasting two menstrual (...) cycles, followed by a randomized, double-blind, placebo-controlled trial of fluoxetine at a dose of either 20 mg or 60 mg per day or placebo for six menstrual cycles. Healthy women meeting criteria for what was then called late-luteal-phase dysphoric disorder were recruited at seven university-affiliated women's health clinics in Canada. The primary outcome measure consisted of visual-analogue scales for tension, irritability, and dysphoria during the late luteal phase of each cycle.Of 405 women

1995 NEJM Controlled trial quality: predicted high

50. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization

Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization Sclar D A, Robison L M, Skaer T L, Galin R S, Legg R F, Nemec N L, Hughes T E, Buesching D P, Morgan M Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Selective Serotonin Reuptake Inhibitors (SSRIs) in antidepressant pharmacotherapy; (a) paroxetine, (b)sertraline, and (c) fluoxetine in the treatment of depression. Type of intervention

1995 NHS Economic Evaluation Database.

51. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. (Abstract)

Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. Amitriptyline reduces the pain caused by peripheral-nerve disease, but treatment is often limited by side effects related to the drug's many pharmacologic actions. Selective agents might be safer and more effective.We carried out two randomized, double-blind, crossover studies in patients with painful diabetic neuropathy, comparing amitriptyline with the relatively selective blocker of norepinephrine reuptake (...) desipramine in 38 patients, and comparing the selective blocker of serotonin reuptake fluoxetine with placebo in 46 patients. Fifty-seven patients were randomly assigned to a study as well as to the order of treatment, permitting comparison among all three drugs and placebo as the first treatment. The patients rated the degree of pain present each day using verbal descriptors, and they also assessed the extent of pain relief globally at the end of each treatment period.After individual dose titration

1992 NEJM Controlled trial quality: uncertain